Back to top

crispr: Archive

Zacks Equity Research

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

VRTXPositive Net Change BLUEPositive Net Change EDITPositive Net Change CRSPNegative Net Change

Andrew Rocco

5 Reasons to be Bullish into 2024

Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks even higher into the new year.

NVONegative Net Change NVDANegative Net Change IMGNPositive Net Change QQQPositive Net Change IWMPositive Net Change KREPositive Net Change CRSPNegative Net Change METANegative Net Change

Kevin Cook

Bull of the Day: CRISPR Therapeutics (CRSP)

FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future

CRSPNegative Net Change VRTXPositive Net Change EDITPositive Net Change

Zacks Equity Research

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

NVONegative Net Change VRTXPositive Net Change CTMXNegative Net Change CRSPNegative Net Change